Table 2.
Clinical data of patient series over the follow-up period
| SSO group |
Densiron 68 group |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IOP baseline | OH% 1 day postoperative | OH% 1 month postoperative | OH% 3 month postoperative | OH% 6 month postoperative | OH% 12 month postoperative | IOP baseline | OH% 1 day postoperative | OH% 1 month postoperative | OH% 3 month postoperative | OH% 6 month postoperative | OH% 12 month postoperative |
| 14.5 ± 6 | 14 (15/105) | 11.4 (12/105) | 11.4 (12/105) | 8.5 (9/105) | 7.6 (8/105)b | 15.2 ± 4 | 20 (15/75) | 16 (12/75) | 14.6 (11/75) | 13.3 (10/75) | 10.6 (8/75)b |
| 15/0* | 11/1a | 8/0a | 15/0a | 9/2a | 8/0a | ||||||
a
Notes: % patients on treatment with topical IOP-lowering drops/surgical treatment;
b
No statistically significant difference between the two groups.
Abbrevations: SSO, standard silicone oil; IOP, intraocular pressure; OH, ocular hypertension is defined as elevated IOP greater than 25 mmHg or greater than 10 mmHg above the preoperative level.